New developments in the treatment of partial-onset epilepsy

Neuropsychiatric Disease and Treatment

Volumn 8, Issue , 2012, Pages 455-464

  Besag, Frank M C ^a,b   Patsalos, Philip N ^c,d  

^a Mid Beds Clinic ^*  (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d EPILEPSY SOCIETY   (United Kingdom)

Author keywords

Antiepileptic drugs; Difficult to treat epilepsy; Partial onset seizures

Indexed keywords

AMPA RECEPTOR; CARBAMAZEPINE; ESLICARBAZEPINE; ETIRACETAM; FELBAMATE; GABAPENTIN; HARKOSERIDE; OXCARBAZEPINE; PERAMPANEL; PLACEBO; PREGABALIN; RETIGABINE; RUFINAMIDE; STIRIPENTOL; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ANOREXIA; ANTI N METHYL D ASPARTATE RECEPTOR ENCEPHALITIS; APLASTIC ANEMIA; ARTICLE; ATAXIA; BLURRED VISION; BRAIN INFECTION; BRAIN MALFORMATION; BRAIN TUMOR; COGNITIVE DEFECT; CONFUSION; DEGENERATIVE DISEASE; DIPLOPIA; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG SAFETY; DYSPHASIA; FATIGUE; FETUS MALFORMATION; FOCAL EPILEPSY; GENETIC ASSOCIATION; HEADACHE; HUMAN; INTELLIGENCE QUOTIENT; LETHARGY; LIVER TOXICITY; MENTAL DISEASE; NAUSEA; NEPHROLITHIASIS; NONHUMAN; NYSTAGMUS; PANCREATITIS; PARKINSONISM; PARTIAL ONSET EPILEPSY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PROTEIN FUNCTION; SEDATION; SIDE EFFECT; SOMNOLENCE; SYSTEMIC LUPUS ERYTHEMATOSUS; TRAUMATIC BRAIN INJURY; TREMOR; VISUAL DISORDER; VISUAL FIELD DEFECT; VOMITING;

EID: 84868103404     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S25099     Document Type: Article

References (80)

1. Kwan P, Brodie MJ. Effectiveness of first antiepileptic drug. Epilepsia. 2001;42:1255-1260.
2. Brodie MJ, Kwan P. Staged approach to epilepsy management. Neurology. 2002;58:S2-S8.
3. Aldenkamp AP, Alpherts WC. The effect of the new antiepileptic drug rufinamide on cognitive functions. Epilepsia. 2006;47:1153-1159.
4. Besag FM. Behavioural effects of the new anticonvulsants. Drug Saf. 2001;24:513-536.
5. Jacoby A, Snape D, Baker GA. Determinants of quality of life in people with epilepsy. Neurol Clin. 2009;27:843-863.
6. Cramer JA, Brandenburg NA, Xu X, Vera-Llonch M, Oster G. The impact of seizures and adverse effects on global health ratings. Epilepsy Behav. 2007;11:179-184.
7. Eke T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. BMJ. 1997;314:180-181.
8. Felbamate linked to aplastic anemia; warning issued on drug's use. Am J Hosp Pharm. 1994;51(19):2324.
9. Pellock JM. Felbamate in epilepsy therapy: evaluating the risks. Drug Saf. 1999;21:225-239.
10. Besag FM, Dodd S. When can a drug be declared "safe"? Curr Drug Saf. 2010;5:112-113.
11. Chadwick D, Smith D. The misdiagnosis of epilepsy. BMJ. 2002;324: 495-496.
12. Uldall P, Alving J, Hansen LK, Kibaek M, Buchholt J. The misdiagnosis of epilepsy in children admitted to a tertiary epilepsy centre with paroxysmal events. Arch Dis Child. 2006;91:219-221.
13. McIntosh AM, Wilson SJ, Berkovic SF. Seizure outcome after temporal lobectomy: current research practice and findings. Epilepsia. 2001;42: 1288-1307.
14. Wiebe S, Blume WT, Girvin JP, Eliasziw M; Effectiveness and Efficiency of Surgery for Temporal Lobe Epilepsy Study Group. A randomized, controlled trial of surgery for temporal-lobe epilepsy. New Engl J Med. 2001;345(5):311-318.
15. Colonnelli MC, Cross JH, Davies S, et al. Psychopathology in children before and after surgery for extratemporal lobe epilepsy. Dev Med Child Neurol. 2012;54:521-526.
16. Glosser G, Zwil AS, Glosser DS, O'Connor MJ, Sperling MR. Psychiatric aspects of temporal lobe epilepsy before and after anterior temporal lobectomy. J Neurol Neurosurg Psychiatry. 2000;68:53-58.
17. Blumer D, Wakhlu S, Davies K, Hermann B. Psychiatric outcome of temporal lobectomy for epilepsy: incidence and treatment of psychiatric complications. Epilepsia. 1998;39:478-486.
18. Marangell LB, Rush AJ, George MS, et al. Vagus nerve stimulation (VNS) for major depressive episodes: one year outcomes. Biol Psychiatry. 2002;51:280-287.
19. Klinkenberg S, Majoie HJ, van der Heijden MM, Rijkers K, Leenen L, Aldenkamp AP. Vagus nerve stimulation has a positive effect on mood in patients with refractory epilepsy. Clin Neurol Neurosurg. 2012;114:336-340.
20. Lockman J, Fisher RS. Therapeutic brain stimulation for epilepsy. Neurol Clin. 2009;27:1031-1040.
21. Scheffer IE, Berkovic SF. The genetics of human epilepsy. Trends Pharmacol Sci. 2003;24:428-433.
22. Besag FMC. Advances in epilepsy. Curr Opin Psychiatry. 1999;12: 549-553.
23. Berkovic SF, Mulley JC. The first gene for an idiopathic epilepsy: a fruitful collaboration of Australian clinical research and molecular genetics [editorial]. Aust N Z J Med. 1996;26:154-156.
24. Dibbens LM, Tarpey PS, Hynes K, et al. X-linked protocadherin 19 mutations cause female-limited epilepsy and cognitive impairment. Nat Genet. 2008;40:776-781.
25. Guerrini R, Dravet C, Genton P, Belmonte A, Kaminska A, Dulac O. Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia. 1998;39:508-512.
26. Chiron C, Dulac O, Beaumont D, Palacios L, Pajot N, Mumford J. Therapeutic trial of vigabatrin in refractory infantile spasms. J Child Neurol. 1991;Suppl 2:S52-S59.
27. Lowenstein DH. Epilepsy after head injury: an overview. Epilepsia. 2009;50 Suppl 2:4-9.
28. Duncan JS. Imaging and epilepsy. Brain. 1997;120:339-377.
29. Vincent A, Bien CG, Irani SR, Waters P. Autoantibodies associated with diseases of the CNS: new developments and future challenges. Lancet Neurol. 2011;10:759-772.
30. Glauser T, Ben-Menachem E, Bourgeois B, et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2006;47:1094-1120.
31. National Institute for Health and Clinical Excellence. The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care. NICE clinical guideline 137. Issued: Jan 2012. Available from: http://guidance.nice.org.uk/CG137. Accessed August 19, 2012.
32. Aldenkamp AP, Alpherts WCJ, Diepman L, Van't Slot B, Overweg J, Vermeulen J. Cognitive side-effects of phenytoin compared with carbamazepine in patients with localization-related epilepsy. Epilepsy Res. 1994;19:37-43.
33. Werlin SL, Fish DL. The spectrum of valproic acid-associated pancreatitis. Pediatrics. 2006;118:1660-1663.
34. Morrow J, Russell A, Guthrie E, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry. 2006;77:193-198.
35. Adab N, Kini U, Vinten J, et al. The longer term outcome of children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry. 2004;75:1575-1583.
36. Meador KJ, Baker GA, Browning N, et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med. 2009; 360:1597-1605.
37. Leppik IE. Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure. 2004;13 Suppl 1:S5-S9.
38. White JR, Walczak TS, Marino SE, Beniak TE, Leppik IE, Birnbaum AK. Zonisamide discontinuation due to psychiatric and cognitive adverse events: a case-control study. Neurology. 2010;75:513-518.
39. Meldrum BS. Update on the mechanism of action of antiepileptic drugs. Epilepsia. 1996;37 Suppl 6:S4-S11.
40. Coulter DA. Antiepileptic drug cellular mechanisms of action: where does lamotrigine fit in? J Child Neurol. 1997;12 Suppl 1:S2-S9.
41. Zheng C, Yang K, Liu Q, etal. The anticonvulsive drug lamotrigine blocks neuronal {alpha}4{beta}2 nicotinic acetylcholine receptors. J Pharmacol Exp Ther. 2010;335:401-408.
42. Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet. 2007;369:1000-1015.
43. Guberman AH, Besag FM, Brodie MJ, et al. Lamotrigine-associated rash: risk/benefit considerations in adults and children. Epilepsia. 1999;40:985-991.
44. Sabers A, Buchholt JM, Uldall P, Hansen EL. Lamotrigine plasma levels reduced by oral contraceptives. Epilepsy Res. 2001;47:151-154.
45. Schmutz M, Brugger F, Gentsch C, McLean MJ, Olpe HR. Oxcarbazepine: preclinical anticonvulsant profile and putative mechanisms of action. Epilepsia. 1994;35 Suppl 5:S47-S50.
46. Johannessen AC, Nielsen OA. Hyponatremia induced by oxcarbazepine. Epilepsy Res. 1987;1:155-156.
47. Rho JM, Donevan SD, Rogawski MA. Mechanism of action of the anticonvulsant felbamate: opposing effects on N-methyl-D-aspartate and gamma-aminobutyric acidA receptors. Ann Neurol. 1994;35: 229-234.
48. Gee NS, Brown JP, Dissanayake VU, Offord J, Thurlow R, Woodruff GN. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. J Biol Chem. 1996;271: 5768-5776.
49. Perucca E, Bialer M. The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine. Clin Pharmacokinet. 1996;31:29-46.
50. Aldenkamp AP, Baker G, Mulder OG, et al. A multicenter, randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial-onset seizures. Epilepsia. 2000;41:1167-1178.
51. 2+channels through an intracellular pathway. Mol Pharmacol. 2012;82:199-208.
52. Li Z, Taylor CP, Weber M, etal. Pregabalin is a potent and selective ligand for α(2)δ-1 and α(2)δ-2calcium channel subunits. Eur J Pharmacol. 2011;667:80-90.
53. Arroyo S. Rufinamide. Neurotherapeutics. 2007;4:155-162.
54. Elger CE, Stefan H, Mann A, Narurkar M, Sun Y, Perdomo C. A 24-week multicenter, randomized, double-blind, parallel-group, dose-ranging study of rufinamide in adults and adolescents with inadequately controlled partial seizures. Epilepsy Res. 2010;88:255-263.
55. Poisson M, Huguet F, Savattier A, Bakri-Logeais F, Narcisse G. A new type of anticonvulsant, stiripentol. Pharmacological profile and neurochemical study. Arzneimittelforschung. 1984;34:199-204.
56. Giraud C, Treluyer JM, Rey E, et al. In vitro and in vivo inhibitory effect of stiripentol on clobazam metabolism. Drug Metab Dispos. 2006;34: 608-611.
57. Fattore C, Perucca E. Novel medications for epilepsy. Drugs. 2011;71: 2151-2178.
58. Patsalos PN, Berry DJ. Pharmacotherapy of the third-generation AEDs: lacosamide, retigabine and eslicarbazepine acetate. Expert Opin Pharmacother. 2012;13:699-715.
59. Elger C, Halasz P, Maia J, Almeida L, Soares-da-Silva P; Investigators Study Group. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study. Epilepsia. 2009;50:454-463.
60. Gil-Nagel A, Lopes-Lima J, Almeida L, Maia J, Soares-da-Silva P; Investigators Study Group. Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures. Acta Neurol Scand. 2009;120:281-287.
61. Ben-Menachem E, Gabbai AA, Hufnagel A, Maia J, Almeida L, Soares-da-Silva P. Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy. Epilepsy Res. 2010;89:278-285.
62. Errington AC, Stohr T, Heers C, Lees G. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol Pharmacol. 2008;73:157-169.
63. Chung S, Sperling MR, Biton V, et al. Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial. Epilepsia. 2010; 51:958-967.
64. Chung S, Ben-Menachem E, Sperling MR, et al. Examining the clinical utility of lacosamide: pooled analyses of three phase II/III clinical trials. CNS Drugs. 2010;24:1041-1054.
65. Main MJ, Cryan JE, Dupere JR, Cox B, Clare JJ, Burbidge SA. Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine. Mol Pharmacol. 2000;58:253-262.
66. Wuttke TV, Seebohm G, Bail S, Maljevic S, Lerche H. The new anticonvulsant retigabine favors voltage-dependent opening of the Kv7.2 (KCNQ2) channel by binding to its activation gate. Mol Pharmacol. 2005;67:1009-1017.
67. +channels. Mol Pharmacol. 2009;75:272-280.
68. Porter RJ, Partiot A, Sachdeo R, Nohria V, Alves WM; Study Group. Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures. Neurology. 2007;68:1197-1204.
69. Brodie MJ, Lerche H, Gil-Nagel A, etal. Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy. Neurology. 2010;75:1817-1824.
70. French JA, Abou-Khalil BW, Leroy RF, et al. Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy. Neurology. 2011;76:1555-1563.
71. Rogawski MA. Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Curr. 2011;11:56-63.
72. Sveinbjornsdottir S, Sander JW, Upton D, et al. The excitatory amino acid antagonist D-CPP-ene (SDZ EAA-494) in patients with epilepsy. Epilepsy Res. 1993;16:165-174.
73. Pitkanen A, Mathiesen C, Ronn LC, Moller A, Nissinen J. Effect of novel AMPA antagonist, NS1209, on status epilepticus. An experimental study in rat. Epilepsy Res. 2007;74:45-54.
74. Fritsch B, Stott JJ, Joelle DJ, Rogawski MA. Treatment of early and late kainic acid-induced status epilepticus with the noncompetitive AMPA receptor antagonist GYKI 52466. Epilepsia. 2010;51:108-117.
75. Rogawski MA. Low affinity channel blocking (uncompetitive) NMDA receptor antagonists as therapeutic agents-toward an understanding of their favorable tolerability. Amino Acids. 2000;19:133-149.
76. Langan YM, Lucas R, Jewell H, et al. Talampanel, a new antiepileptic drug: single-and multiple-dose pharmacokinetics and initial 1-week experience in patients with chronic intractable epilepsy. Epilepsia. 2003;44:46-53.
77. Hanada T, Hashizume Y, Tokuhara N, et al. Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia. 2011;52:1331-1340.
78. Krauss GL, Bar M, Biton V, et al. Tolerability and safety of perampanel: two randomized dose-escalation studies. Acta Neurol Scand. 2012;125:8-15.
79. French J, Elger C, Goldberg-Stern H. Use of perampanel, a selective, non-competitive AMPA receptor antagonist, as adjunctive therapy in patients with refractory partial onset seizures: results of a global phase III study. Epilepsia. 2011;52:10.
80. Krauss GL, Serratosa JM, Villanueva V, et al. Randomised phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology. 2012;78:1408-1415.